Prescient Therapeutics (PTX) is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of solid and hematological cancers.
The Company’s novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.
First Patient at Moffitt dosed in Phase 1b/2 breast trial
Rodman & Renshaw Global Investment Conference Presentation
PTX presents at Rodman & Renshaw Investment Conference
Appendix 4G and Corporate Governance Statement
Appendix 4E and 2016 Annual Report
USPTO Grants Allowances for Two PTX-200 Patents